MedTrace Logo

Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation

NCT00302627 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2018-08-29

No results posted yet for this study

Summary

Bone is lost rapidly and fractures occur in 10-20% of patients who receive organ transplants within 2 years. The purpose of this study is to evaluate long-term effects of a pamidronate-vitamin D-calcium regimen on bone loss, fractures, and safety in recipients of kidney and heart transplants.

Conditions

  • Transplant Bone Disease

Interventions

DRUG

Pamidronate

60mg or 90mg given at baseline, 6,12,18, and 24 months

DRUG

vitamin D

baseline, 6,12 months

DRUG

Calcium Carbonate

baseline, 6,12 months

Sponsors & Collaborators

  • The Heart Institute of Spokane

    collaborator UNKNOWN

  • Ochsner Health System

    collaborator OTHER

  • University of Washington

    collaborator OTHER

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Katherine R. Tuttle, MD,FASN,FACP · Providence Medical Research Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-31
Primary Completion
2002-11-30
Completion
2002-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00302627 on ClinicalTrials.gov